ACADIA Pharmaceuticals (Nasdaq: ACAD) is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. We currently have five mid-to-late stage clinical programs as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs and major commercial markets. In our most advanced program, we are conducting Phase III trials with pimavanserin for the treatment of Parkinson's disease psychosis. We also have three Phase II-stage clinical programs, including pimavanserin as a co-therapy for schizophrenia, pimavanserin for the treatment of sleep maintenance insomnia, and ACP-104 for the treatment of schizophrenia. We have retained worldwide commercialization rights for all four of these proprietary programs. In addition, we have a neuropathic pain program in Phase II development in collaboration with Allergan.

All of the drug candidates in our product pipeline emanate from discoveries made using our proprietary drug discovery platform. We have assembled a strong team of industry-experienced executives and world-class scientific and clinical advisors to direct the development and commercialization of our product pipeline, and we plan to continue to selectively establish strategic collaborations to advance and maximize our commercial opportunities.

Our headquarters are located in San Diego, California, and we maintain research and development operations in both San Diego and Malmo, Sweden.

 back to top